73 results about "Neuraminidase" patented technology

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The invention discloses a preparation method of an electrochemical biosensor based on neuraminidase, and relates to the field of electrochemical sensors. The method comprises the following steps: preparing N-Gr / MWCNTs, preparing N-Gr / MWCNTs (at) GCE, preparing Ppy / N-Gr / MWCNTs (at) GCE, and preparing NA / Ppy / N-Gr / MWCNTs (at) GCE. According to the electrochemical biosensor based on neuraminidase, MWCNTs and N-Gr are compounded to form an N-Gr / MWCNTs composite material, high-conductivity polypyrrole is polymerized on the N-Gr / MWCNTs composite material through pyrrole, the biosensor without a mediator is prepared, electrons can be directly transmitted between an electrode and a bioactive substance, and the electrochemical biosensor can be used for detecting neuraminidase. The response performance of the sensor is obviously improved; the electrochemical biosensor is based on the NA inhibition principle, is mainly used for rapidly screening antiviral components in traditional Chinese medicines, can realize rapid screening and evaluation of the antiviral components in the traditional Chinese medicines, belongs to a convenient, efficient and low-cost means, and also provides scientific basis and technical support for discovery and evaluation of active components.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The present invention discloses drug-loaded nanoparticles targeting neuraminidase, as well as a preparation method and application thereof, belonging to the technical field of pharmaceutical preparations. The present invention connects polysialic acid and polylactic acid glycolic acid via an ester bond to obtain drug-loaded nanoparticles with stable structure and performance. The drug-loaded nanoparticles have the function of targeting neuraminidase and have relatively high efficiency in entering cells. Furthermore, antibiotics are dispersed in the drug-loaded nanoparticles, and an inflammatory modulator is adsorbed on the surface of the drug-loaded nanoparticles. The drug-loaded nanoparticles can deliver the antibiotics and the inflammatory modulator to Grasseria suis in pigs, releasing the antibiotics and the inflammatory modulator in the slightly acidic environment of the infected site in the pig, thereby efficiently killing Grasseria suis and reducing inflammatory damage caused by bacterial infection and toxic damage of the antibiotics. Therefore, the present invention has good application prospects in the preparation of drugs for preventing and / or treating Grasseria suis infection.

In one aspect, provided herein are immunogenic compositions comprising CpG oligonucleotide adjuvant, and a recombinant neuraminidase, wherein the recombinant neuraminidase comprises a globular head domain of influenza virus neuraminidase and a tetramerization domain, and wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a Nucleozin dimer derivative as well as a preparation method and application thereof. The Nucleozin dimer derivative provided by the invention has relatively good anti-influenza virus activity, can remarkably inhibit the enzyme activity of virus neuraminidase so as to play the anti-influenza virus activity, and has relatively good targeting selectivity and relatively low cytotoxicity. The Nucleozin dimer derivative disclosed by the invention can be applied to preparation of an anti-influenza virus drug or preparation of a neuraminidase inhibitor.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

In one aspect, provided herein are immunogenic compositions comprising CpG oligonucleotide adjuvant, and a recombinant neuraminidase, wherein the recombinant neuraminidase comprises a globular head domain of influenza virus neuraminidase and a tetramerization domain, and wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions.

This invention relates to retroviral gene transfer vectors, particularly lentiviral vectors, pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).

The invention relates to antigen-binding polypeptides specifically binding neuraminidase and / or haemagglutinin protein from Influenza B virus resulting in broadly neutralizing IBV antigen-binding polypeptides or antibodies. More specifically the invention relates to immunoglobulin single variable domains specifically binding NA or HA, which upon fusion to bispecific antigen-binding proteins provide for a broader and improved neutralization capacity as compared to a combination of IBV NA- and HA- targeting ISVDs or antibodies. The invention further relates to the use of said antigen-binding proteins for medical purposes, more specifically in prophylactic or therapeutic treatment of a subject, even more specifically to prevent or treat IBV infections.

Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The present invention belongs to the field of biomedicine, and specifically relates to an extraction method and application of an active ingredient of Shengjiang Powder that inhibits neuraminidase. The extraction method comprises the following steps: (1) preparing a crude extract of Shengjiang Powder: taking silkworm pupa, cicada shell, rhubarb, and turmeric, adding water, heating under reflux for extraction, filtering, concentrating, cooling, adding anhydrous ethanol, filtering, and concentrating to dryness to obtain a crude extract of Shengjiang Powder; (2) extracting the crude extract of Shengjiang Powder with a three-phase extraction solvent, collecting the upper phase, middle phase, and lower phase respectively, repeating the extraction 5 times, concentrating and drying to obtain extracts of each part; (3) subjecting the middle phase extract to high-speed countercurrent chromatography, using an eluent for primary separation and secondary separation according to the elution procedure, and automatically collecting the fractions; (4) concentrating and drying to obtain the active ingredient. The extracted active ingredient is applied to the preparation of a drug that inhibits neuraminidase, providing a basis for the development of such drugs.

Provided are a modified-type neuraminidase, a gene encoding the modified-type neuraminidase, a combination of the modified-type neuraminidase and cathepsin A, a combination of the gene encoding the modified-type neuraminidase and a gene encoding cathepsin A, a vector including said genes, and a pharmaceutical composition containing same. The pharmaceutical composition can be used for the therapy of lysosomal storage disease.

The present invention provides compositions comprising one or more polynucleotides that encode a neuraminidase (NA) polypeptide and a hemagglutinin (HA) polypeptide separated by a furin cleavage site and a self-cleaving 2A polypeptide. Methods of using these compositions to induce an immune response to influenza in a subject are also provided.

Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.

The invention provides a polypeptide, and the sequence of the polypeptide is SVDGKENLI. The polypeptide is separated from sheep colostrum after fermentation of the lactobacillus rhamnosus D8A. The invention further provides application of the polypeptide, and the polypeptide can be applied to preparation of drugs for inhibiting neuraminidase, resisting viruses and promoting lung repair. The invention further provides sheep colostrum which comprises the polypeptide. The invention also provides a preparation method of the sheep colostrum, which comprises the following steps: filtering and pre-sterilizing the sheep colostrum, then carrying out secondary homogenization on the sheep colostrum, carrying out flash sterilization and cooling on the sheep colostrum subjected to secondary homogenization, then adding fructose, carrying out sterilization, inoculating a leavening agent comprising the rhamnosus lactobacillus D8A, and carrying out fermentation, so as to obtain the sheep colostrum. And then carrying out primary homogenization, concentration and freeze-drying to obtain the product.

The invention discloses a method for quantitatively analyzing the content of alpha2-3 acetylneuraminic acid in glycoprotein, which comprises the following steps: firstly, treating a sample containing glycoprotein by using streptococcus pneumoniae acetylneuraminidase, and continuously treating the sample containing glycoprotein by using clostridium perfringens acetylneuraminidase in the same solution; centrifugally separating and taking a separating solution containing two acetylneuraminic acid products outside the centrifugal tube; and detecting and collecting two hydrolysates 2, 7-dehydrated acetylneuraminic acid and the signal intensity of acetylneuraminic acid in a negative ion mode, and calculating the percentage content of alpha2-3 linked acetylneuraminic acid by using a formula. According to the method, the sensitivity of quantitative analysis of alpha2-3 acetylneuraminic acid can be improved, and the time consumption of detection and analysis is reduced.

The present application relates to a kind of polyketide alkaloid hybrid compound and its preparation method and application, wherein, the polyketide alkaloid hybrid compound is selected from at least one of the compounds with the structural formula shown in formula I.The compound 1~6 structure includes an atypical angular anthracene ring polyketide ring and open-loop ternary nitrogen ring, both are novel compounds of skeleton.The polyketide alkaloid hybrid compound of the present application has the activity of inhibiting neuraminidase and influenza virus H1N1 and H3N2, and can be used for preparing anti-influenza virus drugs;Meanwhile, it also has the activity of resisting bacteria and actinomycetes, and can be used for preparing antibacterial agent, with good application prospect.

The present invention relates to a mutated neuraminidase enzyme, or a functional fragment thereof with increased enzymatic activity at alkaline pH, compared to a non-mutated neuraminidase enzyme. The invention further provides nucleic acids encoding the mutant enzyme, a vector, a recombinant cell comprising the nucleic acid and a method for producing the enzyme. Also provided are a method for immunohistochemical (IHC) staining, the use of the mutated enzyme in immunohistochemical (IHC) staining, as well as a kit comprising the mutated enzyme.

Provided herein are modified anti-neuraminidase antibodies or antigen binding fragments thereof, pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of influenza A virus.

This invention discloses a neuraminidase-ROS dual-responsive nanocarrier, its preparation method, and its applications. The raw materials for the nanocarrier include 4-hydroxyphenylboronic acid pinacol ester, N,N'-carbonyldiimidazole, and polysialic acid; the molar ratio of 4-hydroxyphenylboronic acid pinacol ester to N,N'-carbonyldiimidazole is 1:1~3, and the mass ratio of 4-hydroxyphenylboronic acid pinacol ester to polysialic acid is 1:0.1~1. The neuraminidase-ROS dual-responsive nanocarrier of this invention not only efficiently delivers antibacterial and anti-inflammatory drugs, but the carrier itself can also actively regulate the pathological microenvironment (such as scavenging reactive oxygen species), thereby achieving multiple synergistic therapies and improving the overall efficacy against complex bacterial infections.

To provide antibodies against influenza neuraminidase.SOLUTION: The present invention provides an antibody or antigen-binding fragment thereof that binds to a neuraminidase of an influenza virus, the antibody or antigen-binding fragment comprising an immunoglobulin heavy chain variable region comprising specific amino acid sequences, an immunoglobulin light chain variable region comprising specific amino acid sequences, or a combination thereof.SELECTED DRAWING: None

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and / or one or more influenza virus neuraminidase (NA) proteins.

The application discloses an anti-neuraminidase human monoclonal antibody obtained through multiple rounds of in-vitro screening and recombination modification and application thereof, and the application is used for preparing products for preventing, detecting or treating influenza viruses. The monoclonal antibody provided by the application has significant neuraminidase inhibiting activity and broad-spectrum influenza virus antigen binding capacity, and has excellent prevention and treatment effects on various seasonal influenza viruses, thereby providing a new technical option for resisting influenza infection and having important application value.

The present invention discloses a pH / neuraminidase dual-responsive drug-loaded nanoparticle, a preparation method, and an application thereof, belonging to the technical field of pharmaceutical preparations. The drug-loaded nanoparticle comprises polysialic acid and an amino acid, wherein the carboxyl group on the polysialic acid side chain is linked to the amino group in the amino acid via an amide bond. The present invention connects the polysialic acid and the amino acid via an amide bond to obtain a drug-loaded nanoparticle with a stable structure and performance. The drug-loaded nanoparticle has the function of targeting neuraminidase, while having low cytotoxicity and high cell entry efficiency. After an antibiotic drug is linked to the drug-loaded nanoparticle via an ester bond, the drug-loaded nanoparticle can deliver the antibiotic drug to the swine Grasseria in the pig's body, release the antibiotic drug in the slightly acidic environment of the infected site in the pig, and thus effectively kill the swine Grasseria. Therefore, the drug-loaded nanoparticle has good application prospects in the preparation of drugs for preventing and / or treating swine Grasseria infections.

The invention belongs to the field of medicines, and discloses a ganoderma triterpenic acid compound, a preparation method thereof and application of the ganoderma triterpenic acid compound in prevention and treatment of influenza viruses. The ganoderma triterpenic acid compound (24E)-3alpha-hydroxy-7-oxo-lanosta-8, 24-dien-26-oic acid is as shown in a formula I which is described in the specification. Experiments prove that the compound disclosed by the invention has relatively good influenza virus neuraminidase inhibitory activity, and the IC50 of the compound is 18.3 mu M. Researches show that the compound has an application prospect in further development of novel anti-influenza drugs.

The invention belongs to the interdiscipline of traditional Chinese pharmacology, analytical chemistry and materialogy, and relates to the technical field of preparation and application of nano materials, in particular to application of a covalent organic framework material to a fishing neuraminidase inhibitor. The covalent organic framework material comprises a boric acid modified covalent organic framework material; a B-N bond characteristic peak located at 1340 cm <-1 > and a C = N bond characteristic peak located at 1570 cm <-1 > exist in infrared detection. The covalent organic framework material is based on precise regulation and control of the structure and the connection mode of the organic monomer, the enrichment capacity of the covalent organic framework material on a neuraminidase inhibitor is remarkably improved, the inhibition rate of the covalent organic framework material on neuraminidase reaches up to 94.78%, and the covalent organic framework material can serve as a carrier material to be used for enrichment of neuraminidase inhibitor components.